Events Diary




Oligonucleotides for Cardiovascular and Metabolic Disease Summit

Online

02 December 2020 - 02 December 2020



Summary
Overcome Tissue-Specific and Translational Challenges Limiting the Development of Emerging RNA Therapeutics to Address Cardiovascular and Metabolic Disease

Overview
Developed from research with industry leaders, including AstraZeneca, Ionis, and Amgen, this intimate digital conference will pre-competitively advance ASO, RNAi, and RNA therapeutics beyond the liver, by comprehensively analyzing pioneering research and the latest data specific to cardiovascular and cardiometabolic disease in both rare and chronic settings. Hear world-class insights from bench to bedside and troubleshoot clinical challenges with other stakeholders, including maximizing on-target delivery, achieving appropriate dosage and administration, and optimizing clinical trial design to accelerate the development of life-changing therapies for millions of patients worldwide. Join over 40 other oligonucleotide and cardiometabolic drug developers at this uniquely concentrated conference dedicated to advancing the next generation of oligonucleotide therapeutics for cardiometabolic disease.

More Information »

Want to feature posters from your event on ePosters?


As well as increasing visibility and showcasing the quality of your event, ePosters provides a number of benefits for event organizers.
For information on how ePosters would benefit your event please contact us.